EN
首页 资讯 期刊 导师 问答 求职 发Paper 文献直达 高级搜索 期刊列表
当前位置： X-MOL 学术 › Respir. Res. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Correction: Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study
Respiratory Research ( IF 5.8 ) Pub Date : 2024-04-01 , DOI: 10.1186/s12931-024-02745-x
Afisi S. Ismaila , Kieran J. Rothnie , Robert P. Wood , Victoria L. Banks , Lucinda J. Camidge , Alexandrosz Czira , Chris Compton , Raj Sharma , Shannon N. Millard , Olivia Massey , David M. G. Halpin


Correction: Respiratory Research (2023) 24: 229 https://doi.org/10.1186/s12931-023-02523-1


Following publication of the original article [1], the Authors identified errors in the COPD-related total costs for prompt and delayed initiators and the associated exponentiated coefficient (95% confidence interval) and p-value in Fig. 8b.

The corrected Fig. 8b is given below:

These errors also impacted some statements under the “Results” and “Discussion” sections and “Conclusions”. This text has now been amended in this Correction.

HCRU and costs following FF/UMEC/VI initiation.

The text in the penultimate sentence under the heading “HCRU and costs following FF/UMEC/VI initiation” in the “Results” section originally read: Prompt initiators had numerically lower all-cause total costs and significantly lower COPD-related costs per-person-per-year compared with delayed initiators (Fig. 8; COPD-related costs: prompt £742, delayed £801, p = 0.0016).

Corrected sentence: Prompt initiators had numerically lower all-cause total costs and similar COPD-related costs per-person-per-year compared with delayed initiators (Fig. 8).

The first sentence of the second “Discussion” paragraph originally read: Prompt initiation of FF/UMEC/VI following the index exacerbation was also associated with fewer all-cause and COPD-related hospital readmissions at all time points assessed, as well as lower COPD-related total costs and COPD-related prescription costs compared with delayed initiation.

Corrected sentence: Prompt initiation of FF/UMEC/VI following the index exacerbation was also associated with fewer all-cause and COPD-related hospital readmissions at all time points assessed, as well as lower COPD-related prescription costs compared with delayed initiation.

Finally, an additional discrepancy in the “Conclusions” section is noted.

The first sentence originally read: Compared with delayed initiation, prompt initiation of FF/UMEC/VI following a moderate/severe exacerbation was associated with fewer subsequent exacerbations, fewer hospital readmissions, and lower COPD-related medical costs.

Corrected sentence: Compared with delayed initiation, prompt initiation of FF/UMEC/VI following a moderate/severe exacerbation was associated with fewer subsequent exacerbations, fewer hospital readmissions, and lower COPD-related prescription costs.

The Authors apologise for these discrepancies and for any inconvenience to the journal and to the readers.

The original article has been corrected.

  1. Ismaila AS, Rothnie KJ, Wood RP, Banks VL, Camidge LJ, Czira A, Compton C, Sharma R, Millard SN, Massey O, Halpin DMG. Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study. Respir Res. 2023;24:229. https://doi.org/10.1186/s12931-023-02523-1.

    Article CAS PubMed PubMed Central Google Scholar

Download references

Author notes

  1. Victoria L. Banks and Shannon N. Millard were affiliated with Adelphi Real World at the time of the study.

Authors and Affiliations

  1. Value Evidence and Outcomes, R&D Global Medical, GSK, 1250 South Collegeville Road, Collegeville, PA, USA

    Afisi S. Ismaila

  2. Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada

    Afisi S. Ismaila

  3. Value Evidence and Outcomes, R&D Global Medical, GSK, London, UK

    Kieran J. Rothnie & Alexandrosz Czira

  4. Real-World Evidence, Adelphi Real World, Bollington, Cheshire, UK

    Robert P. Wood, Victoria L. Banks, Lucinda J. Camidge, Shannon N. Millard & Olivia Massey

  5. Integrated Evidence Generation (Women’s Health Care), Bayer PLC, Reading, UK

    Victoria L. Banks

  6. Global Medical, GSK, London, UK

    Chris Compton & Raj Sharma

  7. P1vital Limited, Wallingford, Oxfordshire, UK

    Shannon N. Millard

  8. College of Medicine and Health, University of Exeter Medical School, University of Exeter, Exeter, UK

    David M. G. Halpin

Authors
  1. Afisi S. IsmailaView author publications

    You can also search for this author in PubMed Google Scholar

  2. Kieran J. RothnieView author publications

    You can also search for this author in PubMed Google Scholar

  3. Robert P. WoodView author publications

    You can also search for this author in PubMed Google Scholar

  4. Victoria L. BanksView author publications

    You can also search for this author in PubMed Google Scholar

  5. Lucinda J. CamidgeView author publications

    You can also search for this author in PubMed Google Scholar

  6. Alexandrosz CziraView author publications

    You can also search for this author in PubMed Google Scholar

  7. Chris ComptonView author publications

    You can also search for this author in PubMed Google Scholar

  8. Raj SharmaView author publications

    You can also search for this author in PubMed Google Scholar

  9. Shannon N. MillardView author publications

    You can also search for this author in PubMed Google Scholar

  10. Olivia MasseyView author publications

    You can also search for this author in PubMed Google Scholar

  11. David M. G. HalpinView author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Afisi S. Ismaila.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ismaila, A.S., Rothnie, K.J., Wood, R.P. et al. Correction: Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study. Respir Res 25, 152 (2024). https://doi.org/10.1186/s12931-024-02745-x

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/s12931-024-02745-x

Share this article

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative



中文翻译：
更正：英格兰 COPD 患者急性加重后立即开始单吸入器糠酸氟替卡松、芜地溴铵和维兰特罗 (FF/UMEC/VI) 的益处：一项回顾性队列研究


更正：呼吸研究（2023）24：229 https://doi.org/10.1186/s12931-023-02523-1


在原始文章 [1] 发表后，作者在图 8b 中发现了与 COPD 相关的即时和延迟启动剂总成本以及相关指数系数（95% 置信区间）和 p 值中的错误。

修正后的图8b如下：

这些错误还影响了“结果”和“讨论”部分以及“结论”下的一些陈述。该文本现已在本更正中进行了修改。

FF/UMEC/VI 启动后的 HCRU 和成本。

“结果”部分中“ HCRU 和 FF/UMEC/VI 启动后的成本”标题下的倒数第二句中的文本原文如下： 迅速启动者的全因总成本较低，并且人均 COPD 相关成本显着降低- 与延迟启动者相比每年（图 8；COPD 相关费用：即时 742 英镑，延迟 801 英镑，p = 0.0016）。

更正句子：与延迟启动者相比，及时启动者的全因总成本较低，且每人每年与慢性阻塞性肺病相关的成本相似（图 8）。

第二个“讨与延迟启动相比，相关总成本和 COPD 相关处方成本。

更正句子：与延迟开始治疗相比，在指数恶化后立即开始 FF/UMEC/VI 还与评估的所有时间点的全因和 COPD 相关再入院率减少有关，并且与 COPD 相关的处方费用较低。

最后，注意到“结论”部分中的另一个差异。

第一句话原文为：与延迟启动相比，中度/重度恶化后立即启动 FF/UMEC/VI 与较少的后续恶化、较少的再入院和较低的 COPD 相关医疗费用相关。

更正的句子：与延迟启动相比，中度/重度恶化后立即启动 FF/UMEC/VI 与较少的后续恶化、较少的再入院和较低的 COPD 相关处方费用相关。

作者对这些差异以及给期刊和读者带来的任何不便表示歉意。

原文章已更正。

  1. Ismaila AS、Rothnie KJ、Wood RP、Banks VL、Camidge LJ、Czira A、Compton C、Sharma R、Millard SN、Massey O、Halpin DMG。英国 COPD 患者急性加重后立即开始使用单吸入器糠酸氟替卡松、芜地溴铵和维兰特罗 (FF/UMEC/VI) 的益处：一项回顾性队列研究。呼吸研究。 2023；24:229。 https://doi.org/10.1186/s12931-023-02523-1。

    文章 CAS PubMed PubMed Central Google Scholar

下载参考资料

作者笔记

  1. Victoria L. Banks 和 Shannon N. Millard 在进行研究时隶属于 Adelphi Real World。

作者和单位

  1. 价值证据和成果，R&D Global Medical，GSK，1250 South Collegeville Road, Collegeville, PA, USA

    阿菲西·伊斯梅拉

  2. 麦克马斯特大学健康研究方法、证据和影响系，加拿大安大略省汉密尔顿

    阿菲西·伊斯梅拉

  3. 价值证据和成果，R&D Global Medical，葛兰素史克，英国伦敦

    基兰·J·罗斯尼 (Kieran J. Rothnie) 和亚历山德罗斯·奇拉 (Alexandrosz Czira)

  4. 真实世界证据，Adelphi Real World，英国柴郡博灵顿

    罗伯特·P·伍德、维多利亚·L·班克斯、露辛达·J·卡米奇、香农·N·米勒德和奥利维亚·梅西

  5. 综合证据生成（女性保健），拜耳公司，雷丁，英国

    维多利亚湖班克斯

  6. 全球医疗，葛兰素史克，英国伦敦

    克里斯·康普顿和拉杰·夏尔马

  7. P1vital Limited，英国牛津郡沃灵福德

    香农·米勒德

  8. 医学与健康学院，埃克塞特大学医学院，埃克塞特大学，埃克塞特英国

    大卫·MG·哈尔平

作者
  1. Afisi S. Ismaila查看作者出版物

    您也可以在PubMed Google Scholar中搜索该作者 

  2. Kieran J. Rothnie查看作者出版物

    您也可以在PubMed Google Scholar中搜索该作者 

  3. 罗伯特·P·伍德查看作者出版物

    您也可以在PubMed Google Scholar中搜索该作者 

  4. 维多利亚·班克斯 (Victoria L. Banks)查看作者出版物

    您也可以在PubMed Google Scholar中搜索该作者 

  5. Lucinda J. Camidge查看作者出版物

    您也可以在PubMed Google Scholar中搜索该作者 

  6. Alexandrosz Czira查看作者出版物

    您也可以在PubMed Google Scholar中搜索该作者 

  7. 克里斯·康普顿查看作者出版物

    您也可以在PubMed Google Scholar中搜索该作者 

  8. Raj Sharma查看作者出版物

    您也可以在PubMed Google Scholar中搜索该作者 

  9. Shannon N. Millard查看作者出版物

    您也可以在PubMed Google Scholar中搜索该作者 

  10. 奥利维亚·梅西查看作者出版物

    您也可以在PubMed Google Scholar中搜索该作者 

  11. David MG Halpin查看作者出版物

    您也可以在PubMed Google Scholar中搜索该作者 

通讯作者

通讯作者：Afisi S. Ismaila。

出版商备注

施普林格·自然对于已出版的地图和机构隶属关系中的管辖权主张保持中立。

开放获取本文根据知识共享署名 4.0 国际许可证获得许可，该许可证允许以任何媒介或格式使用、共享、改编、分发和复制，只要您对原作者和来源给予适当的认可，提供知识共享许可的链接，并指出是否进行了更改。本文中的图像或其他第三方材料包含在文章的知识共享许可中，除非材料的出处中另有说明。如果文章的知识共享许可中未包含材料，并且您的预期用途不受法律法规允许或超出了允许的用途，则您需要直接获得版权所有者的许可。要查看此许可证的副本，请访问 http://creativecommons.org/licenses/by/4.0/。知识共享公共领域奉献豁免 (http://creativecommons.org/publicdomain/zero/1.0/) 适用于本文中提供的数据，除非数据的信用额度中另有说明。

转载和许可

检查更新。通过 CrossMark 验证货币和真实性

引用这篇文章

伊斯梅拉 (Ismaila)、AS、罗思尼 (Rothnie)、KJ、伍德 (Wood) RP等人。更正：英格兰 COPD 患者急性加重后立即开始单吸入器糠酸氟替卡松、芜地溴铵和维兰特罗 (FF/UMEC/VI) 的益处：一项回顾性队列研究。呼吸研究 25 , 152 (2024)。 https://doi.org/10.1186/s12931-024-02745-x

下载引文

  • 发表：

  • DOI ：https://doi.org/10.1186/s12931-024-02745-x

分享此文章

您与之分享以下链接的任何人都可以阅读此内容：

抱歉，本文目前没有可共享的链接。

由 Springer Nature SharedIt 内容共享计划提供
更新日期：2024-04-01
  点击分享   查看原文
点击收藏
公开下载
阅读更多本刊最新论文 本刊介绍/投稿指南
down
wechat
bug